281 related articles for article (PubMed ID: 31413564)
1. Arsenic sulfide nanoformulation induces erythroid differentiation in chronic myeloid leukemia cells through degradation of BCR-ABL.
Wang T; Wen T; Li H; Han B; Hao S; Wang C; Ma Q; Meng J; Liu J; Xu H
Int J Nanomedicine; 2019; 14():5581-5594. PubMed ID: 31413564
[TBL] [Abstract][Full Text] [Related]
2. Aclacinomycin A sensitizes K562 chronic myeloid leukemia cells to imatinib through p38MAPK-mediated erythroid differentiation.
Lee YL; Chen CW; Liu FH; Huang YW; Huang HM
PLoS One; 2013; 8(4):e61939. PubMed ID: 23613979
[TBL] [Abstract][Full Text] [Related]
3. Caveolin-1 contributes to realgar nanoparticle therapy in human chronic myelogenous leukemia K562 cells.
Shi D; Liu Y; Xi R; Zou W; Wu L; Zhang Z; Liu Z; Qu C; Xu B; Wang X
Int J Nanomedicine; 2016; 11():5823-5835. PubMed ID: 27853367
[TBL] [Abstract][Full Text] [Related]
4. As4S4 targets RING-type E3 ligase c-CBL to induce degradation of BCR-ABL in chronic myelogenous leukemia.
Mao JH; Sun XY; Liu JX; Zhang QY; Liu P; Huang QH; Li KK; Chen Q; Chen Z; Chen SJ
Proc Natl Acad Sci U S A; 2010 Dec; 107(50):21683-8. PubMed ID: 21118980
[TBL] [Abstract][Full Text] [Related]
5. Induction of K562 Cell Apoptosis by As4S4 via Down-Regulating miR181.
Gong J; Zheng S; Zhang L; Wang Y; Meng J
Med Sci Monit; 2017 Jan; 23():144-150. PubMed ID: 28072759
[TBL] [Abstract][Full Text] [Related]
6. Apoptosis and erythroid differentiation triggered by Bcr-Abl inhibitors in CML cell lines are fully distinguishable processes that exhibit different sensitivity to caspase inhibition.
Jacquel A; Colosetti P; Grosso S; Belhacene N; Puissant A; Marchetti S; Breittmayer JP; Auberger P
Oncogene; 2007 Apr; 26(17):2445-58. PubMed ID: 17043649
[TBL] [Abstract][Full Text] [Related]
7. Chlorogenic acid inhibits Bcr-Abl tyrosine kinase and triggers p38 mitogen-activated protein kinase-dependent apoptosis in chronic myelogenous leukemic cells.
Bandyopadhyay G; Biswas T; Roy KC; Mandal S; Mandal C; Pal BC; Bhattacharya S; Rakshit S; Bhattacharya DK; Chaudhuri U; Konar A; Bandyopadhyay S
Blood; 2004 Oct; 104(8):2514-22. PubMed ID: 15226183
[TBL] [Abstract][Full Text] [Related]
8. Novel agent nitidine chloride induces erythroid differentiation and apoptosis in CML cells through c-Myc-miRNAs axis.
Liu N; Li P; Zang S; Liu Q; Ma D; Sun X; Ji C
PLoS One; 2015; 10(2):e0116880. PubMed ID: 25647305
[TBL] [Abstract][Full Text] [Related]
9. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D
Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
[TBL] [Abstract][Full Text] [Related]
10. Combined effects of As4S4 and imatinib on chronic myeloid leukemia cells and BCR-ABL oncoprotein.
Yin T; Wu YL; Sun HP; Sun GL; Du YZ; Wang KK; Zhang J; Chen GQ; Chen SJ; Chen Z
Blood; 2004 Dec; 104(13):4219-25. PubMed ID: 15339852
[TBL] [Abstract][Full Text] [Related]
11. CD69 partially inhibits apoptosis and erythroid differentiation via CD24, and their knockdown increase imatinib sensitivity in BCR-ABL-positive cells.
Huang SY; Liu YH; Chen YJ; Yeh YY; Huang HM
J Cell Physiol; 2018 Sep; 233(9):7467-7479. PubMed ID: 29663362
[TBL] [Abstract][Full Text] [Related]
12. Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L).
Perkins C; Kim CN; Fang G; Bhalla KN
Blood; 2000 Feb; 95(3):1014-22. PubMed ID: 10648417
[TBL] [Abstract][Full Text] [Related]
13. Novel Mechanism by a Bis-Pyridinium Fullerene Derivative to Induce Apoptosis by Enhancing the MEK-ERK Pathway in a Reactive Oxygen Species-Independent Manner in BCR-ABL-Positive Chronic Myeloid Leukemia-Derived K562 Cells.
Sumi K; Tago K; Nakazawa Y; Takahashi K; Ohe T; Mashino T; Funakoshi-Tago M
Int J Mol Sci; 2022 Jan; 23(2):. PubMed ID: 35054935
[TBL] [Abstract][Full Text] [Related]
14. Activin A downregulates the CD69-MT2A axis via p38MAPK to induce erythroid differentiation that sensitizes BCR-ABL-positive cells to imatinib.
Chen CW; Huang NK; Lee YL; Fan CK; Chen YC; Liu CW; Huang HM
Exp Cell Res; 2022 Aug; 417(2):113219. PubMed ID: 35643179
[TBL] [Abstract][Full Text] [Related]
15. Wogonin induces cell cycle arrest and erythroid differentiation in imatinib-resistant K562 cells and primary CML cells.
Yang H; Hui H; Wang Q; Li H; Zhao K; Zhou Y; Zhu Y; Wang X; You Q; Guo Q; Lu N
Oncotarget; 2014 Sep; 5(18):8188-201. PubMed ID: 25149543
[TBL] [Abstract][Full Text] [Related]
16. Acetylshikonin induces apoptosis of human leukemia cell line K562 by inducing S phase cell cycle arrest, modulating ROS accumulation, depleting Bcr-Abl and blocking NF-κB signaling.
Hao G; Zhai J; Jiang H; Zhang Y; Wu M; Qiu Y; Fan C; Yu L; Bai S; Sun L; Yang Z
Biomed Pharmacother; 2020 Feb; 122():109677. PubMed ID: 31810012
[TBL] [Abstract][Full Text] [Related]
17. Novel oxime derivatives of radicicol induce erythroid differentiation associated with preferential G(1) phase accumulation against chronic myelogenous leukemia cells through destabilization of Bcr-Abl with Hsp90 complex.
Shiotsu Y; Neckers LM; Wortman I; An WG; Schulte TW; Soga S; Murakata C; Tamaoki T; Akinaga S
Blood; 2000 Sep; 96(6):2284-91. PubMed ID: 10979978
[TBL] [Abstract][Full Text] [Related]
18. Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds.
Aichberger KJ; Mayerhofer M; Krauth MT; Vales A; Kondo R; Derdak S; Pickl WF; Selzer E; Deininger M; Druker BJ; Sillaber C; Esterbauer H; Valent P
Cancer Res; 2005 Oct; 65(20):9436-44. PubMed ID: 16230407
[TBL] [Abstract][Full Text] [Related]
19. Apoptotic effect of As2S2 on K562 cells and its mechanism.
Li JE; Wu WL; Wang ZY; Sun GL
Acta Pharmacol Sin; 2002 Nov; 23(11):991-6. PubMed ID: 12421474
[TBL] [Abstract][Full Text] [Related]
20. Growth inhibitory effect of dihydroartemisinin on Bcr/Abl+ chronic myeloid leukemia K562 cells involve AKT, ERK and NF-κB modulation.
Lee J; Zhang G; Wu X; Xu F; Zhou J; Zhang X
J Cancer Res Clin Oncol; 2012 Dec; 138(12):2095-102. PubMed ID: 22833150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]